In particular, the improvement in clinical indices was associated with decreased expression of genes responsible for regulating cell proliferation (MTOR, p21), survival (ULK1), and apoptosis (caspase 3) in the peripheral blood from RA patients after RTX treatment to the level observed in healthy controls. This evidence concerns the gene MTOR and rheumatoid arthritis.